250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotech VC Funds in Germany

A list of 50 VC funds that invest in Biotech startups based in Germany. We rank investors based on the number of investments they made in Biotech companies from Germany. We update this investor list every month.

Top 50 Biotech VC Funds in Germany

Investor Biotech Germany investments
High-Tech Grunderfonds 25
NRW.BANK 15
KfW 15
Boehringer Ingelheim Venture Fund 14
MIG 14
TGFS - Technologiegründerfonds Sachsen 8
Wellington Partners 8
Bayern Kapital 7
IFB Innovationsstarter 7
coparion 6
eCAPITAL ENTREPRENEURIAL PARTNERS 6
BioMedPartners 6
Creathor Ventures 5
bm-t beteiligungsmanagement thuringen 5
Gilde Healthcare 4
Seed Fonds Aachen 4
Brandenburg Kapital 4
Amino Collective 4
Life Sciences Partners 4
Forbion Capital Partners 4
bmp Ventures 4
S-Venture Capital Dortmund 4
EMBL Ventures 4
BayBG Venture Capital 4
TVM Capital 3
UVC Partners 3
German Federal Ministry of Education and Research (BMBF) 3
IBB Ventures 3
Grazia Equity 3
Think.Health 3
Andera Partners 3
Seventure Partners 3
BlueYard Capital 3
CPT Capital 3
Cascara Ventures 3
Global Asset Fund 3
VC Fonds Technologie Berlin 2
Pacira Pharmaceuticals 2
Sunstone Life Science Ventures 2
LBBW VC 2
Monkfish Equity 2
Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG) 2
Peppermint Venture Partners 2
Vesalius Biocapital Partners 2
S-Refit 2
Born2Grow 2
Possible Ventures 2
Good Seed Ventures 2
TVM Capital Life Science 2
TQ Ventures 2
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
High-Tech Grunderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 47 investments in the past 12 months
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • DeepScenario — DeepScenario provides real-world traffic data with high accuracy to help companies build the world’s most intelligent driver.
  • Grand perspective — Grandperspective scanfeld is the first remote sensing solution for automated early-warning gas leak detection in chemical plants.
  • GS Bavaria — GS Bavaria is a manufacturer of industrial-scale nano-sized carbide powders. The production of the nanomaterials is extremely cost-efficient, sustainable and with minimal energy consumption due to the revolutionary bioleaching extraction process for tungsten, tungsten carbide and other metals.
NRW.BANK VC Fund · Düsseldorf, Nordrhein-Westfalen, Germany · 9 investments in the past 12 months
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.
Show more
Investment focus
  • Science/Engineering, Software, Health Care
  • Seed, Series A, Series B
  • Germany, United States
Portfolio highlights
  • Catch — Catch is a HR SaaS Company
  • consalio — The advisor spend management solution that helps management to stay in control of the advisor spend.
  • Drop Friends — Nie wieder den Postboten verpassen
KfW VC Fund · Frankfurt, Hessen, Germany · 3 investments in the past 12 months
KfW gives impetus to economic, social and ecological development worldwide. As a promotional bank under the ownership of the Federal Republic and the Länder (federal states), it offers support to encourage sustainable improvement in economic, social, ecological living and business conditions, among others in the areas of small and medium-sizedenterprise, entrepreneurialship, environmental protection, housing, infrastructure, education finance, project and export finance, and development cooperation.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Funding Round
  • Germany, India, Kenya
Portfolio highlights
  • Electrochaea — Electrochaea is commercializing a disruptive, scalable technology to convert electric power into methane, the principal component of natural gas. Using CO2 as a feedstock gas, power can be efficiently converted to renewable natural gas for power storage, for transportation fuels, or for transmission via a natural gas network. The company licensedtechnology from the University of Chicago and is led by the Nidus Partners, a St. Louis investment group specializing in renewable energy. Mich Hein, a Nidus Managing Partner, serves as CEO.Electrochaea has developed a commercially viable and disruptive solution for utility-scale energy storage, grid balancing, and carbon reuse. Their proprietary process converts low-cost and stranded electricity and carbon dioxide into pipeline-grade renewable gas for direct injection into the existing natural gas grid, a conversion process known as “power-to-gas”.
  • Uniper — Uniper is an international energy company with about 11,000 employees. They combine a balanced portfolio of technologically advanced large-scale assets with outstanding technical and commercial expertise. Uniper is a German energy company based in Dusseldorf, North Rhine-Westphalia. It was formed by the separation of E.ON's fossil fuel assetsinto a separate company that began operating on 1 January 2016.
  • NamPower — NamPower is the national power utility of Namibia and specializes in the generation and transmission of electricity.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 8 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
  • C-mo Medical Solutions — C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
MIG VC Fund · München, Bayern, Germany
Zusammen gestalten wir die Unternehmen von morgen.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series A, Funding Round, Series B
  • Germany, Austria, Canada
Portfolio highlights
  • NavVis — NavVis next-generation technology for the built environment enables accurate mobile mapping of indoor spaces and enterprise-ready digital twin solutions.
  • Bolt — Logistics, Simplified. GoBolt is building a sustainable, first-party supply chain network. Delivering an end-to-end customer experience.
  • IOmx Therapeutics — iOmx Therapeutics focuses on the development of first-in-class cancer therapeutics addressing novel immune checkpoint modulators on tumor cells. By systematically screening human tumor cells, the Company has already identified a number of novel targets and analyzed their mode of action.The Company was founded on the successful concept of cancerimmune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Immune resistance of tumors is often mediated by cell surface molecules that stimulate immune-inhibitory receptors on T cells. Reactivating the host immune response by neutralizing these negative interactions is the idea behind cancer immune-checkpoint therapy.
TGFS - Technologiegründerfonds Sachsen VC Fund · Leipzig, Sachsen, Germany · 5 investments in the past 12 months
TGFS - Technologiegruenderfonds Sachsen is an early stage VC fund targeting high tech startups with strong growth potential. The fund invests into ventures located in Saxony/Germany, Europe's leading semiconductor cluster. The team has invested into more than 120 companies so far, including more than 40 investments from the currentfund.
Show more
Investment focus
  • Software, Hardware, Science/Engineering
  • Seed, Funding Round, Series A
  • Germany, United States
Portfolio highlights
  • WAKU Robotics — WAKU Robotics enables warehouses, DCs, and factories to select, implement, and operate the best robotic solutions. Mobile robots can be compared and procured via our marketplace ‘Lotsofbots.com’. We represent all major robot brands and are committed to extending their sales reach. Our SaaS product ‘WAKU Sense’, an agnostic robot control tower,enables robot operators to increase robot utilization, reduce downtime, and prevent vendor lock-in.
  • Foodcall — Foodcall offers voice bot for restaurants.
  • Cinector — Cinector GmbH develops and licenses tools for rapid media production and easy 3D visualization.Cinector software gives end users the power to produce impressive visualizations, a power which in the past was reserved for trained specialists or pricey agencies. However, media experts also benefit, as our products speed up their production cyclesimmensely.
Wellington Partners VC Fund · Munich, Bayern, Germany · 7 investments in the past 12 months
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more
Investment focus
  • Health Care, Science/Engineering, Software
  • Series A, Series B, Funding Round
  • Germany, United States, United Kingdom
Portfolio highlights
  • Orcan Energy — Orcan Energy is the leader in waste heat recovery technology.Orcan Energy GmbH was founded in 2008, as a spin-out from the Technical University of Munich (“TUM”). Orcan’s ePack offers a compact, service-reduced and cost- efficient “plug-and-play” waste heat power generator based on ORC-Technology. Spe- cific patented innovations enable Orcan topopularize the technology on the mass mar- ket. At the beginning of 2013, Orcan gained sponsorships from the Exist-Research- Transfer-Aid of the Federal Government of Germany and additional grants from the “Wissensfabrik” and various resources from the TUM.
  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgiation.
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Bayern Kapital VC Fund · Landshut, Bayern, Germany · 16 investments in the past 12 months
Bayern Kapital (founded at the end of 1995) is a wholly owned subsidiary of the LfA Foerderbank Bayern (Bavaria‘s development bank). Bayern Kapital’s objective is to finance research and development as well as the market launch of new products, product diversifications, and expansion of the market share.The requesting company has to be located inBavaria. Industries are e. g. IT/software, life sciences, new materials, micro-systems and environmental technologies.Bayern Kapital and its funds have invested in more than 250 companies and currently manages funds to the value of EUR 340 m. The five investing funds currently managed by Bayern Kapital are Seedfonds Bayern, Clusterfonds Start-Up!, Innovationsfonds, Innovationsfonds EFRE and Wachstumsfonds Bayern.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Seed, Series A, Funding Round
  • Germany, United States, Finland
Portfolio highlights
  • WORKERBASE — Agile manufacturing to increase production flexibility and ensure business continuity. Intelligent process execution for the connected worker to increase operational flexibility and reduce costs in Industry 4.0
  • Munevo — Munevo empowers people with disabilities by using smart and innovative technology.
  • Quantum Systems — Our vision is to become the global leader in providing aerial data for decision making by the use of our drones.
IFB Innovationsstarter VC Fund · Hamburg, Hamburg, Germany · 3 investments in the past 12 months
The IFB Innovationsstarter is an innovation funding and investment company of the City of Hamburg providing grants and investments.
Show more
Investment focus
  • Software, Science/Engineering, Health Care
  • Seed, Funding Round, Grant
  • Germany, United States
Portfolio highlights
  • NTRDE - The Global Trade OS — NTRDE is a software company that helps Global Trade companies make smarter decisions by leveraging existing knowledge and increasing the efficiency of daily business transactions. NTRDE promotes intelligent automation and predictive services while reducing manual work within existing processes.
  • Emmora — Emmora vision is to create a comprehensive, cross-target digital companion on the topics of death, grief and life. It organizes funerals according to their wishes. With selected local partners, guarantee a smooth process.
  • Dealcode GmbH — Make your sales team data-driven and leverage the value of AI guided selling to increase win-rates and revenue.
coparion VC Fund · Cologne, Nordrhein-Westfalen, Germany · 9 investments in the past 12 months
Coparion provides venture capital to accelerate momentum and growth. With a currently active fund of EUR 275 million, Coparion has the means to do so.Coparion supports entrepreneurial vision with know-how, but without intervening in daily business operations. Thanks to in-depth experience in venture capital and in building companies, the Coparionteam discerns potential and opens up new perspectives. Coparion has the substance, tenacity, and creativity required to mutually manage difficult situations successfully.Coparion only invests with co-investors. The fund invests up to EUR 15M per company, usually in several financing rounds of EUR 0.5-8M each. The investment focus is on German companies in the start-up and early growth phases. Coparion is based in Cologne and Berlin.
Show more
Investment focus
  • Software, Science/Engineering, Data and Analytics
  • Series A, Seed, Series B
  • Germany, Switzerland, United States
Portfolio highlights
  • 35up — Boost your revenue with our cross-selling platform and never lose revenue to the big marketplaces again. Get to know 35up in a free demo now!
  • Autovio — Autovio offers digital concepts for driving schools.
  • CNC24 — The leading manufacturing-as-a-service platform for high quality precision parts in Europe.
eCAPITAL ENTREPRENEURIAL PARTNERS VC Fund · Münster, Nordrhein-Westfalen, Germany · 2 investments in the past 12 months
eCAPITAL is a venture capital investor that provides early to growth stage funding to technology and deep tech companies.
Show more
Investment focus
  • IT, Science/Engineering, Software
  • Series A, Funding Round, Series B
  • Germany, United States, Italy
Portfolio highlights
  • Dryad Networks — Overview of Dryad, providing ultra-early fire detection as well as forest growth and health monitoring.
  • Tenzir — Tenzir empowers defenders by developing an open security analytics platform that automates detection and investigation of attacks. Based in Hamburg, Germany, Tenzir is an open-core company committed to data-centric decision support for security operations. Tenzir’s customers include large enterprises and managed security service providers.
  • Sweepatic — A user-friendly platform that automates the discovery and security analysis of your online attack surface.
BioMedPartners VC Fund · Basel, Basel-Stadt, Switzerland · 5 investments in the past 12 months
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
  • Switzerland, Germany, France
Portfolio highlights
  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgiation.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Creathor Ventures VC Fund · Bad Homburg, Hessen, Germany
We have been investing at the frontier of technology and science for over 30 years. We know what it takes to succeed.
Show more
Investment focus
  • Software, Internet, Health Care
  • Series A, Funding Round, Series B
  • Germany, Switzerland, United States
Portfolio highlights
  • HeyJobs — Intelligent recruiting | more hires with performance marketing | only qualified candidates | fast recruiting success | over 1,500 companies use HeyJobs to find employees
  • Ledgy — Digitize your cap table, automate equity plans and simplify compliance. Find out how leading companies use Ledgy to empower their employees and engage investors.
  • Humanoo — HUMANOO | MAKING PEOPLE HEALTHIER! HUMANOO is the digital health platform for employees and insurance clients. We enable our users to improve their physical and mental health. Simple, effective, proven - all in one app. With customized programs and innovative eHealth solutions, we guide our users in the areas of fitness, physio, yoga, mindfulnessand nutrition to their self-imposed goals. For the first time, companies and insurance companies can use comprehensive decentralized analysis to understand the health of their employees or insurance clients and make it a measurable success. Our team currently consists of 65 employees from 15 nations with different talents. In our office in Berlin-Kreuzberg, software developers, designers, marketing and sales specialists work together with sports and nutrition scientists as well as yoga teachers and physiotherapists. What we share is the goal to motivate people to stay healthy.
bm-t beteiligungsmanagement thuringen VC Fund · Erfurt, Thuringen, Germany
bm-t beteiligungsmanagement thüringen is a regional venture capital and private equity company with fokus on investments in the State of Thüringen in Germany only. We invest in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.
Show more
Investment focus
  • Software, Health Care, IT
  • Seed, Funding Round, Series A
  • Germany, United States
Portfolio highlights
  • Coachwhisperer — Mit dem weltweit ersten Live Kommunikations- und Monitoring-System kann der Trainer mit all seinen Spielern auf dem Feld sprechen.
  • tediro — tediro develops a mobile robotics platform for multiple applications in healthcare primarily therapy and diagnostics
  • rooom.com — rooom is a global startup based in Germany, launched in 2019. The company’s experienceCloud is an all-in-one platform for creating, managing and promoting engaging 2D, 3D, AR & VR experiences. It works across all desktop and mobile devices. rooom’s experienceCloud is designed to cover the marketing and visualization needs of differentindustries through their comprehensive product portfolio. These include eventCloud (optimized for virtual events, exhibitions, conferences, meetings), spaceCloud (real estate, property, museums), productCloud (3D products, product showrooms) and immerseCloud (tours, guides, 3D books). rooom’s eventCloud is routinely hosting up to 200,000 users for hybrid events like IFA, Berlin and for global customers such as Porsche, Deutsche Telekom, DHL and E.ON. rooom has won over 20 awards, including the Global Eventex Award (twice), the Innovation & Excellence Award and the German Innovation Award.
Gilde Healthcare VC Fund · Utrecht, Utrecht, The Netherlands · 5 investments in the past 12 months
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series C, Series A, Series B
  • United States, The Netherlands, Germany
Portfolio highlights
  • Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
  • Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
  • Splice Bio — We are working with our proprietary platform to address key limitations of current gene therapy approaches to treat patients in need.
Seed Fonds Aachen VC Fund · Aachen, Nordrhein-Westfalen, Germany
Seed Fonds has a strong competence network with national and international investors, business angels & expertes from the industry. They are specialized in the development of comprehensive financing models offering stability and development opportunities on the long term.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Seed, Funding Round, Series A
  • Germany
Portfolio highlights
  • Hemovent — ​​​Based in Aachen, Germany, Hemovent is a privately held medical technology company that is developing a portable ECMO (Extra Corporeal Membrane Oxygenation) unit. Hemovent was founded by serial entrepreneur, Christof Lenz and Oliver Marseille, inventors of the company’s proprietary platform. It is the goal of the company to develop aninnovative solution, with precision and craftsmanship, that will aide patients with lung and heart function while allowing them to be mobile.
  • aquila biolabs — aquila biolabs is a German technology company focusing on the development of innovative laboratory devices for the analysis of shake-flask fermentations in biotechnological, chemical and pharmaceutical research and development.
  • miacosa — miacosa.de is operated by the Endorsed Goods GmbH. miacosa.de is a social shopping concept from Germany based in Cologne. Social Shopping the miacosa way means that members select their personal shopping team of experts and celebrities that present products they love on miacosa.de Miacosa is for members only. The free service starts with productsfrom the fields of Health Style, Home & Living, Kitchen and fashion accessories.
Brandenburg Kapital VC Fund · Potsdam, Brandenburg, Germany · 9 investments in the past 12 months
With a track record of over 20 years in venture capital and experience from more than 200 investments in numerous companies BFB Brandenburg Kapital GmbH (BFB) is the most active equity investor in Brandenburg. BFB invests in fast-growing technology-orientated companies throughout the whole life-cycle. Target sectors are ICT/Digital Economy,Life Science, MedTech, Proptech, Industrial Applications. BFB invests in companies based in or with facilities in Brandenburg. The current VC fund is financed by the European Regional Development Fund (ERDF) an Investitionsbank des Landes Brandenburg (ILB).
Show more
Investment focus
  • Software, Science/Engineering, Internet
  • Seed, Series A, Funding Round
  • Germany, United Kingdom
Portfolio highlights
  • Grand perspective — Grandperspective scanfeld is the first remote sensing solution for automated early-warning gas leak detection in chemical plants.
  • Kupando — Kupando is a biopharmaceutical company that develops agonists to stimulates innate immunity.
  • Envoria — Certified Software for Sustainability Reporting and Green Controlling. Covering GRI, EU Taxonomy, CSRD, ESRS, and more.
Amino Collective VC Fund · Berlin, Berlin, Germany · 10 investments in the past 12 months
Amino Collective empowers entrepreneurs and scientists to transform healthcare and biotech.
Show more
Investment focus
  • Health Care, Software, Biotechnology
  • Seed, Series A, Pre-Seed
  • Germany, United States, United Kingdom
Portfolio highlights
  • Hedera Dx — A diagnostics platform that makes liquid biopsies a reality in cancer care
  • Kernal Biologics — Kernal biologics is an onco-selective mRNA therapeutics company located in Cambridge, MA
  • Aware — Aware is a mobile app for evaluating health data and for researching chronic diseases.
Life Sciences Partners VC Fund · Amsterdam, Noord-Holland, The Netherlands · 7 investments in the past 12 months
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing to private and public life-science companies. Since the late 1980s, LSP's management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. For example,LSP was a founding investor in Crucell, DNage, Qiagen, Rhein Biotech and Pharming. With over EUR 500 million under management and offices in Amsterdam, Munich and Boston, LSP is one of Europe's largest and most experienced specialist life-science investors.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • eTheRNA immunotherapies — eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases.
  • ImCheck Therapeutics — ImCheck Therapeutics is a developer of immuno-modulatory antibodies designed for the treatment of cancer and other immune-related diseases. The company's services are engaged in the discovery and development of immunomodulators for treating breast cancer, gastric, ovarian cancer cells and other solid solid tumours.
  • Ariceum Therapeutics — Ariceum Therapeutics focuses on diagnosis and precision treatment of neuroendocrine and certain other aggressive, hard-to-treat cancers.
Forbion Capital Partners VC Fund · Naarden, Noord-Holland, The Netherlands · 9 investments in the past 12 months
Impacting the future of medicine.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Series A, Series C
  • United States, United Kingdom, The Netherlands
Portfolio highlights
  • Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • F2G — F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity.
bmp Ventures VC Fund · Berlin, Berlin, Germany · 2 investments in the past 12 months
bmp Ventures is an innovative Venture Capital Company from Berlin. Since 1997 we’ve been investing Smart Money in Early Stage and Growth Startups. We finance ingenious business models with outstanding teams, who build fast-growing and sustainably profitable enterprises.
Show more
Investment focus
  • Software, IT, Manufacturing
  • Seed, Funding Round, Series A
  • Germany, United States, Austria
Portfolio highlights
  • InLine-Med — Radiologists perform safe, precise & easy interventions with the InLine-Med surgical tools and assistance devices.
  • Wingfield — Wingfield ist dein Zugang zu einem virtuellen Tenniserlebnis.
  • Solar Materials — Solar Materials primarily engages in the development of technologies for the sustainable and economical recycling of solar modules.
S-Venture Capital Dortmund VC Fund · Deutsch, Sachsen, Germany
S-Venture Capital Dortmund aims to fund technology companies and is a German regional investment group.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series B, Funding Round, Series C
  • Germany
Portfolio highlights
  • Protagen — Protagen is a precision medicine specialist that support drug development, facilitate treatment strategies and improve patient management. Protagen is at the forefront of immuno-profiling and the discovery of novel autoantibody signatures for autoimmune disease and immuno-oncology. Protagen’s SeroTag® technology identifies biomarkers that address anumber of challenges currently hindering the successful development and broader application of both cancer immunotherapies and novel treatments for autoimmune diseases.The company is a leader in patient stratification for autoimmune disease, having developed disease-specific NavigAID stratification panels that profile individual patient’s autoimmune condition and immune status. This precision medicine approach allows for the development and implementation of more targeted therapies for diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), Sjögren’s syndrome (SjS) and others.
  • Innolume — Innolume has invented a novel comb laser light engine for short-reach optical interconnects between and within computers. Economical wavelength-division multiplexing (WDM) is enabled by this class of low-cost, low-power Fabry-Perot lasers. WDM, familiar from telecom, provides an efficient alternative to multiple lasers and underutilized parallelfiber/waveguides, reducing short-reach system cost and power.
  • Scienion — SCIENION AG is a life science company well positioned in the markets of ultra-low volume liquid handling systems and microarray technologies. They provide their customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomicsand proteomics fields – from early research to manufacturing.
EMBL Ventures VC Fund · Heidelberg, Baden-Wurttemberg, Germany
EMBL Ventures invest throughout Europe with the aim to build companies that create significant commercial opportunities based on new therapeutic treatment.
Show more
Investment focus
  • Biotechnology, Science/Engineering, Health Care
  • Series B, Series A, Series D
  • Germany, Austria, United Kingdom
Portfolio highlights
  • Topas Therapeutics — Topas Therapeutics GmbH is a private Hamburg, Germany-based biotechnology company focused on developing products to address areas of major unmet need, including autoimmune diseases, allergies and anti-drug antibodies. The Topas Particle Conjugates technology platform induces antigen-specific immune tolerance by harnessing the liver’s naturalimmunology capabilities. The Company has several proprietary programs; lead product candidate TPM203 has recently entered clinical testing for pemphigus vulgaris, an orphan disease. Other programs are in anti-drug antibodies, celiac disease, Type 1 diabetes, as well as a multiple sclerosis program that is available for partnering.Topas has a research and option agreement with Eli Lilly and Company focused on antigen-specific tolerance induction and a multi-year agreement with Boehringer Ingelheim to collaborate in the field of anti-drug antibodies.Topas’ investors include: Epidarex Capital, Gimv, EMBL Ventures, Evotec and Boehringer Ingelheim Venture Fund.
  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
  • Arsanis — Arsanis is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build andadvance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets.The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).
BayBG Venture Capital VC Fund · München, Bayern, Germany · 7 investments in the past 12 months
Innovative post-revenue startups with first customers trust us as highly reliable investors. We have been an active player in the venture capital market for over 25 years. Due to our evergreen approach, we offer institutional venture capital without the limitations of the usual fund structure. Predominantly we invest straight equity. Additionally,we can offer venture debt to mature startups close to break-even in order to avoid further dilution for founders. Being a private investment company we act as both lead investor or co-investor. We can also fulfill the private lead investor role for public investors like Bayern Kapital. Together we are increasing YOUR company's value.
Show more
Investment focus
  • Software, IT, Hardware
  • Funding Round, Series B, Series A
  • Germany, Italy, United States
Portfolio highlights
  • Munevo — Munevo empowers people with disabilities by using smart and innovative technology.
  • Rebike Mobility — rebike1 purchases new E-Bikes from Top manufactures and brands like Winora/Haibike, Husqvarna, Flyer, KTM, Orbea. After renting the E-Bikes to businesses and consumers, the fully refurbished E-Bikes are sold with a 2 yr. warranty on rebike1. rebike1 also purchases used stock of E-Bikes from rental stations and retailers and sell them fullyrefurbished to consumers. In Oberstdorf, a Top tourist location south of Munich, rebike1 operates the largest E-Bike rental station in the area. Under the brand ebike1verleih, the rental business is expanding within tourist areas in partnership with local bike-shops. rebike1 GmbH was founded 2018 and has 18 employees today.
  • Goodly Innovations — Goodly Innovations is the leading regulated industry-focused global Pharma 4.0 provider for extended reality shop floor guidance. From cleanrooms to secondary packaging areas, labs and more, Goodly can help improve Pharma and BioPharma clients efficiency, OEE, quality, training and more
TVM Capital VC Fund · Munich, Bayern, Germany
TVM Capital Group is an affiliation of globally acting venture capital and private equity firms with an operating track record of more than 30 years.
Show more
Investment focus
  • Science/Engineering, Biotechnology, Health Care
  • Series C, Series D, Series B
  • United States, France, Germany
Portfolio highlights
  • Rapid Micro Biosystems — Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration. The company was formerly known as Genomic Profiling Systems and changed its name to RapidMicro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
  • Proteon Therapeutics — Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases.The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics.Proteon Therapeutics’ first drug candidate (PRT-201) is indevelopment for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).
  • Argos Therapeutics — ABOUT ARGOS People Powered, Patient Driven PRECISION IMMUNOTHERAPY Addressing Cancer & HIV INVESTORS News & Stock Information
UVC Partners VC Fund · Munich, Bayern, Germany · 14 investments in the past 12 months
UVC Partners is a Munich- and Berlin-based early-stage venture capital firm that invests in technology-based startups in the areas of enterprise software, industrial technologies, and mobility. The fund typically invests between € 0.5 - 10m initially and up to € 20m in total per company.
Show more
Investment focus
  • Software, Science/Engineering, IT
  • Seed, Series A, Series B
  • Germany, Switzerland, Denmark
Portfolio highlights
  • paretos — Become a leader in the new era of AI with paretos! Leading AI-based decision intelligence platform to make effective, data-driven decisions.
  • Synera (ex-ELISE) — Accelerate product development and unlock potential with powerful workflows that connect your data, tools and teams.
  • Wire — Wire is the most secure collaboration platform, transforming the way businesses communicate at the same speed and with the same impact that our founders disrupted telephony with Skype. Headquartered in Berlin with offices in Switzerland and San Francisco, Wire’s award-winning collaboration and communications platform counts over 1,800 governmentand enterprise customers worldwide, including EY, Fortum, the German government and four other G7 governments. Recognized for its secure collaboration platform as a leader and high performer by G2 Crowd, IDC, Forrester and Gartner, Wire offers messaging, audio/video conferencing, file-sharing, and external collaboration - all protected by the most advanced end-to-end encryption.
German Federal Ministry of Education and Research (BMBF) VC Fund · Bonn, Nordrhein-Westfalen, Germany
German Federal Ministry of Education and Research (BMBF)
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Grant, Seed, Series B
  • Germany, United States, Denmark
Portfolio highlights
  • Evotec — Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances,development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes, and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased, and comprehensive infrastructure.Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB, and others. In addition, the company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Sanofi in the field of diabetes and cancer immunotherapy, with Pfizer in the field of tissue fibrosis, with Bayer in the field of kidney diseases, and with Celgene in the field of neurodegenerative diseases.
  • InflaRx — InflaRx develops new therapeutics in the field of acute and chronic inflammation and consists of a team of internationally recognized researchers and clinicians who have dedicated their careers to translate discoveries and expertise into new therapeutic concepts for clinical application.In April 2018, InflaRx conducted a USD 117 million totalgross proceeds follow-on transaction on the US Nasdaq global select market comprised of a primary component of USD 63 million investment into InflaRx as well as a secondary component of USD 54 million to existing first-day shareholders of InflaRx. InflaRx was founded in December 2017 and is headquartered in Jena, Germany.
  • Verovaccines — VEROVACCiNES discovers and develops innovative vaccine solutions, to protect animals against infectious diseases. Key is a novel, broadly applicable, yeast-based technology to generate subunit marker vaccines. This technology has been validated by demonstrating protection of several target animal species against different viral diseases(proof-of-concept).VEROVACCiNES GmbH is a spin-off company of the Martin Luther University Halle-Wittenberg, Germany in 2017. The company exclusively took over IP, brand, team, products and know-how from the former BMBF GO-Bio-funded VEROVACCiNES project at Halle University. VEROVACCiNES GmbH is eligible for follow-up phase 2 funding from the same BMBF GO-Bio program. They cooperate closely with veterinary pharmaceutical companies, universities and research institutes, and they are eager to initiate new collaborations.
IBB Ventures VC Fund · Berlin, Berlin, Germany · 14 investments in the past 12 months
IBB Ventures is for all those who make a difference and create a sustainable future. We invest public funds as venture capital and, together with Berlin startups, help to promote our capital as a business location.
Show more
Investment focus
  • Software, Health Care, Internet
  • Seed, Funding Round, Series A
  • Germany, United States, United Kingdom
Portfolio highlights
  • Seniovo — Barrierefreier Badumbau - alles aus einer Hand und zum Nulltarif inkl. Zuschussbeantragung und Einholen der Vermietergenehmigung // Sorgenfrei und schnell
  • Jomigo — We enable companies and freelance recruiters to successfully fill positions in our collaboration marketplace.
  • Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.
Grazia Equity VC Fund · Stuttgart, Baden-Wurttemberg, Germany · 3 investments in the past 12 months
Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.
Show more
Investment focus
  • Internet, Software, Science/Engineering
  • Series A, Seed, Series B
  • Germany, United States, Switzerland
Portfolio highlights
  • VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
  • Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!
  • itravel — itravel allows leisure travelers to configure and book experiences, hotels, and transportation on tablets, the web, and in social media. itravel offers the client tools to select and “build” custom trips based on desired experiences (such as kitesurfing, elephant rides, special spa treatments), specific room configurations, and personalpreferences. itravel’s app interfaces allow these selections to happen effortlessly and with appealing content.
Think.Health VC Fund · Fürstenfeldbruck, Bayern, Germany · 2 investments in the past 12 months
Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek innovations and disruptive business models in digital healthcare, medical technologies and health service providers,
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Seed, Series A, Series B
  • Germany, United States
Portfolio highlights
  • Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
  • anvajo — Originally started at TU Dresden, anvajo can now look back on several years of innovative research and successful product development with uninterrupted growth. As part of the business expansion and ongoing team building, anvajo moved into its new headquarters in Dresden in January 2020. On 1300 m² practically all areas, including development,production and support functions are united under one roof.
  • Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.
Andera Partners VC Fund · Paris, Ile-de-France, France · 7 investments in the past 12 months
Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Private Equity, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgiation.
  • Resonance Imaging Group — Resonance Imaging Group provides all patients with access to medical imaging, for increasingly precise diagnoses.
  • HR Path — HR Path is a global consultancy with over 500 consultants across North America, Europe and the Middle East, and is solely dedicated to HR Systems Integration, HR Outsourcing, and HR Business Consulting.Co-founded in 2001 by François Boulet and Cyril Courtin, HR Path provides human capital management technology and is an authorized reseller forsoftware solutions in the French market (SAP and SuccessFactors, HR Access, Oracle HCM, Cegid, Sage, Talentsoft). The company has also developed its own HR software solutions, including BiHRdy (a business intelligence decision-making tool), Pandore (a packaged solution for HR, payroll and time management), and Geef (a talent management system).Headquartered in Paris, the company has operations in 13 countries on five continents, employs more than 500 consultants and generates €60 million in annual revenue through its network of agencies in major cities across France and its foreign subsidiaries.The client portfolio includes several CAC 40-listed companies, but also many small and medium-sized enterprises, intermediate-sized firms, and public sector organizations.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 11 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
  • Science/Engineering, Health Care, Biotechnology
  • Series A, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • Clinical Microbiomics — Expert microbiome analysis services, including for gut, oral, skin, and for pre clinical & clinical trials.
  • Standing Ovation — Animal-free dairy cheese
  • Sentryc — Protect your brand and your products from counterfeiters with Sentryc. We monitor over 120 marketplaces for you and remove potential counterfeits.
BlueYard Capital VC Fund · Berlin, Berlin, Germany · 8 investments in the past 12 months
BlueYard backs founders building the interconnected elements that can become the fabric of our future.
Show more
Investment focus
  • Software, Other, Financial
  • Seed, Series A, Funding Round
  • United States, Germany, France
Portfolio highlights
  • Next Matter — Next Matter enables teams to digitize their complex, manual business processes within hours, and realize substantial performance improvements within days. No code, consultants, or IT project management required. Our customers - like HelloFresh and Home24 - design and deploy high-value, end-to-end business processes at a fraction of the time andcost required for typical enterprise-grade solutions. And we’re covering a growing number of teams and use cases across businesses including operations, finance, HR, procurement, logistics, and supplier management.Take the lead on digitization today. Find out how you can use Next Matter to transform your business at https://nextmatter.com.
  • Cryptio — We offer enterprise-grade accounting, reporting, and audit software for your digital assets.
  • Kiln — Stake your treasury directly, or bring staking to your users through our whitelabel product.
CPT Capital VC Fund · London, England, United Kingdom · 7 investments in the past 12 months
Investing in the Future of Protein.We invest in visionary founders creating the future of food and materials.
Show more
Investment focus
  • Gaming, Food/Beverage, Science/Engineering
  • Series A, Seed, Series B
  • United States, Israel, United Kingdom
Portfolio highlights
  • Hoxton Farms — Based in London, UK, Hoxton Farms is growing real animal fat – without animals. The company combines cell biology and mathematical modelling to produce cultivated fat as an ingredient for the meat alternatives industry.
  • Avant Meats — They focus on technology, commercial product innovation, and branding as well as intellectual property portfolio building in the area of ‘cell-based’ animal protein food products.
  • Liberation Labs — Liberation Labs believe that by innovating technology, It can free the world from the costs of industrialized agriculture and unlock a new era of accessible, healthy foods. The mission is to make precision fermentation by commercializing purpose-built manufacturing facilities for industrial biotech.
Cascara Ventures VC Fund · Brussels, Brussels Hoofdstedelijk Gewest, Belgium
96 Normal 0 false false false EN-GB X-NONE X-NONE
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A
  • The Netherlands
Portfolio highlights
  • ATRO Medical — ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype.
  • Surgify — Surgify technology enables surgeons to reduce patient suffering in bone cutting procedures by protecting the vital structures, such as nerves, blood vessels and organs.
  • microDimensions — microDimensions provides digital pathology software and services: image analysis, 3D histology reconstruction, protein multiplexing, stereology, image registration.
Global Asset Fund VC Fund · Landshut, Bayern, Germany
Global Asset Fund is a private equity firm based in Germany that finances early and later stage venture investments. The fund enables the development of products and technologies that address a growing market of tomorrow.
Show more
Investment focus
  • Science/Engineering, Hardware, Health Care
  • Series A, Series B, Funding Round
  • Germany
Portfolio highlights
  • Siltectra — SILTECTRA is a high-tech company specializing in kerfless wafering and thinning, an innovative new technology for manufacturing wafers. Kerfless wafering by SILTECTRA is a platform technology which can be used in a wide variety of industries and for many different materials.
  • Isarna Therapeutics — Isarna Therapeutics has an unmatched commitment to developing selective TGF-β inhibitors to effectively treat ophthalmic diseases. They are advancing a unique pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcomes.
VC Fonds Technologie Berlin VC Fund · Berlin, Berlin, Germany
VC Fonds Technologie Berlin GmbH is a joint initiative of Investitionsbank Berlin (IBB) and the State of Berlin.
Show more
Investment focus
  • Software, Health Care, Video
  • Seed, Series A, Series C
  • Germany
Portfolio highlights
  • Mika — Mika is a digital platform empowering people affected by cancer.
  • German Autolabs — German Autolabs builds powerful voice assistance tools to augment the daily workflows of professional drivers, couriers and delivery teams.
  • OMEICOS Therapeutics — OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling.
Pacira Pharmaceuticals
Pacira Pharmaceuticals Inc. operates as a pharmaceutical company which engages in the development and manufacturing of injectable pharmaceutical products. Pacira Pharmaceuticals Inc. was formerly known as DepoTech Corp. was formerly as SkyePharma Inc. and changed its name to Pacira Pharmaceuticals Inc. in June, 2007. The company was founded in 1989and is based in San Diego, California. Pacira Pharmaceuticals Inc. operates as a subsidiary of Pacira, Inc.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Funding Round, Convertible Note, Seed
Sunstone Life Science Ventures
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Funding Round, Series B, Series A
LBBW VC
LBBW Venture is a venture capital investor focused on DACH based technology innovators. We help brilliant teams with a strong moat to establish visionary market leaders.
Show more
Investment focus
  • Science/Engineering, Software, Health Care
  • Series A, Series B, Funding Round
Monkfish Equity
Monkfish Equity is the investment vehicle of the trivago founders. As Co-investors, with a focus on later stage phases, they invest in companies which can benefit from their entrepreneurial experience. Running the world´s biggest travel meta portal with over 500 M$ revenue (2015), the people behind Monkfish Equity understand entrepreneurs needs andfocus on value adding activities. As “low maintenance” investors, they offer the leeway that entrepreneurs need to build their businesses.
Show more
Investment focus
  • Internet, Commerce/Shopping, Software
  • Seed, Funding Round, Series A
Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG)
The Mittelständische Beteiligungsgesellschaft Niedersachsen (MBG) mbH is an organisation that supports the economy of Lower Saxony.
Show more
Investment focus
  • Health Care, Biotechnology, Community/Lifestyle
  • Seed, Series A, Funding Round
Peppermint Venture Partners
PVP is a private venture capital firm based in Berlin, investing in early-stage healthcare companies across Europe with a focus on medical device, digital health, and platform technology companies. Peppermint VenturePartners was established in 2008 by Ingeborg Neumann, Dr. Joachim Rautter and Dr. Klaus Stöckemann.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Series A, Series B, Series C
Vesalius Biocapital Partners
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds raised since 2007. They have contributed to developing 20 companies since inception.With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financingrounds.Their companies are based in Europe allowing easy interaction with management.They invest in all stages of development and do not shy away from relatively early-stage projects with a sound proprietary technology and corresponding IP, unique team skills and a clear competitive edge based on solid data.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Series B, Series A, Series C
S-Refit
S-Refit is a German venture capital firm that invests in biotechnology, mechanical engineering, and software companies.
Show more
Investment focus
  • Health Care, Biotechnology, Science/Engineering
  • Private Equity
Born2Grow
Born2Grow is a german venture fund focusing on early stage investments. They invest up to 500k€ in innovative business models. They are based in Heilbronn in Baden-Wuerttemberg. Born2Grow focus on investments lies within the MedTech, BioTech, FinTech area as well as some other online industries
Show more
Investment focus
  • Software, Health Care, Internet
  • Seed, Series A, Series B
Possible Ventures
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more
Investment focus
  • Software, Science/Engineering, Hardware
  • Seed, Pre-Seed, Series A
Good Seed Ventures
Good Seed Ventures is a Venture Capital firm that exclusively invests in sustainable food tech.
Show more
Investment focus
  • Gaming, Food/Beverage, Health Care
  • Seed, Series A, Pre-Seed
TVM Capital Life Science
TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.
Show more
Investment focus
  • Health Care, Science/Engineering, Biotechnology
  • Funding Round, Series A, Series B
TQ Ventures
Led by Schuster Tanger, Andrew Marks, and Scooter Braun, TQ Ventures is a leading venture capital firm based in New York City and Los Angeles.
Show more
Investment focus
  • Software, Commerce/Shopping, Internet
  • Seed, Series A, Funding Round
Investors by industry
Investors by country
VC Funds in Germany by industry